Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
LRRK2 and Lipid Pathways: Implications for Parkinson's Disease.
Galper J, Kim W, Dzamko N Biomolecules. 2022; 12(11).
PMID: 36358947 PMC: 9687231. DOI: 10.3390/biom12111597.
References
1.
Ortega R, Torres P, Swan M, Nichols W, Boschung S, Raymond D
. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease. J Clin Neurosci. 2016; 28:185-6.
PMC: 4856562.
DOI: 10.1016/j.jocn.2015.12.004.
View
2.
Gelb M, Scott C, Turecek F
. Newborn screening for lysosomal storage diseases. Clin Chem. 2014; 61(2):335-46.
PMC: 4345406.
DOI: 10.1373/clinchem.2014.225771.
View
3.
Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S
. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58.
PMC: 4564023.
DOI: 10.1093/brain/awv179.
View
4.
Alcalay R, Wolf P, Chiang M, Helesicova K, Zhang X, Merchant K
. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol. 2020; 7(10):1816-1830.
PMC: 7545591.
DOI: 10.1002/acn3.51164.
View
5.
Kate Zhang X, Elbin C, Chuang W, Cooper S, Marashio C, Beauregard C
. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem. 2008; 54(10):1725-8.
DOI: 10.1373/clinchem.2008.104711.
View